CCM
ADVM

CAAS Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

CAAS Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,434
Closed -$128K – 764
2022
Q3 		$128K Buy
+13,434
New +$177K 0.01% 690
2020
Q4 		– Sell
-25,008
Closed -$2.58M – 820
2020
Q3 		$2.58M Buy
+25,008
New +$3.75M 0.06% 234

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAAS Capital Management's ADVM Position: Q4 2022 in Review

CAAS Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 13,434 shares — an estimated $128K sold.

CAAS Capital Management first reported a position in ADVM in Q3 2020 and held it in 2 quarters. The position peaked at $2.58M in Q3 2020. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

  • CAAS Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 13,434 Adverum Biotechnologies shares in Q4 2022, an estimated $128K.
  • CAAS Capital Management first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 2 quarters.
  • CAAS Capital Management's Adverum Biotechnologies position peaked at $2.58M in Q3 2020.
  • 59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.